27th Sep 2019 08:44
(Alliance News) - Pharmaceutical company Indivior PLC on Friday said it awarded a grant as part of a US government initiative to clamp down on opioid misuse.
Indivior develops and commercialises CX3256, a medication "suitable for the treatment" for use disorder of opioid, a substance frequently used for pain relief and offers morphine-like effects.
The grant was one of 375 awards across 41 states made by the National Health Institutes, a part of the US government Department of Health & Human Services.
Indivior Scientific Chief Christian Heidbreder said: "Despite the availability of medications to treat opioid use disorder, there is a need for improved treatment modalities that involve new mechanisms of action. With this award, we will advance C4X3256 from preclinical status through Phase 1 clinical evaluation and perform the necessary toxicology and drug metabolism studies to enable Phase 2 studies."
Opioid use disorder, or opioid addiction, is classified as a chronic disease. In 2018, an estimated 10.3 million people aged 12 or over misused opioids.
Shares in Indivior were 1.9% higher at 46.05 pence each in London on Friday morning.
By Eric Cunha; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Indivior